文献速递皮肤肿瘤

MiR-200a通过靶向CDK6调控转移性黑色素瘤对CDK4/6抑制剂的反应

MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
PubMed 文献 · J Invest Dermatol · 2017-05-16

转移性黑色素瘤中CDK4/6通路常失调,CDK4/6抑制剂显示一定临床活性。本研究发现miR-200a下调CDK6表达,从而降低高增殖性转移性黑色素瘤对CDK4/6抑制剂的反应;miR-200a低表达与疾病进展及淋巴结转移数目增多相关。miR-200a表达受启动子区DNA甲基化和上游增强子区染色质可及性表观遗传调控。过表达miR-200a通过靶向CDK6诱导细胞周期阻滞,降低磷酸化-Rb1和E2F下游靶点水平,抑制细胞增殖;CDK6过表达可逆转这些效应。相反,miR-200a低表达的转移性黑色素瘤细胞CDK6水平更高,对CDK4/6抑制剂反应更显著。作者提出miR-200a作为「细胞周期刹车」在黑色素瘤进展至转移过程中丢失,可用于识别高增殖且更可能对CDK4/6抑制剂有反应的黑色素瘤。

要点

  • miR-200a通过靶向CDK6降低CDK4/6抑制剂在转移性黑色素瘤中的反应。
  • miR-200a低表达与疾病进展和淋巴结转移数目增多相关。
  • miR-200a低表达者CDK6高,对CDK4/6抑制剂反应更显著。

核心结论

  • miR-200a作为细胞周期刹车在黑色素瘤转移中丢失,其低表达提示对CDK4/6抑制剂更敏感。

研究设计与样本

  • 基于转移性黑色素瘤细胞的实验研究,涉及miR-200a表达调控及CDK6靶向机制。

主要发现

  • miR-200a下调CDK6表达,降低高增殖性转移性黑色素瘤对CDK4/6抑制剂的反应。
  • miR-200a低表达与疾病进展及淋巴结转移数目增多相关。
  • miR-200a表达受启动子区DNA甲基化和上游增强子区染色质可及性表观遗传调控。
  • 过表达miR-200a通过靶向CDK6诱导细胞周期阻滞,降低磷酸化-Rb1和E2F下游靶点水平,抑制增殖,CDK6过表达可逆转。
  • miR-200a低表达的转移性黑色素瘤细胞CDK6水平更高,对CDK4/6抑制剂反应更显著。

临床怎么用

  • miR-200a低表达或CDK6高表达的转移性黑色素瘤可能更受益于CDK4/6抑制剂,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The CDK4/6 pathway is frequently dysregulated in cutaneous melanoma. Recently, CDK4/6 inhibitors have shown promising clinical activity against several cancer types, including melanoma. Here, we show that microRNA-200a decreases CDK6 expression and thus reduces the response of CDK4/6 inhibitor in highly proliferative metastatic melanoma. Down-regulation of microRNA-200a expression in melanoma cells is associated with disease progression and a higher number of lymph node metastases. Furthermore, microRNA-200a expression is epigenetically modulated by both DNA methylation at the promoter region and chromatin accessibility of an upstream genomic region with enhancer activity. Mechanistically, overexpression of miR-200a in metastatic melanoma cells induces cell cycle arrest by targeting CDK6 and decreases the levels of phosphorylated-Rb1 and E2F-downstream targets, diminishing cell proliferation; these effects are recovered by CDK6 overexpression. Conversely, low microRNA-200a expression in metastatic melanoma cells results in higher levels of CDK6 and a more significant response to CDK4/6 inhibitors. We propose that microRNA-200a functions as a "cell cycle brake" that is lost during melanoma progression to metastasis and provides the ability to identify melanomas that are highly proliferative and more prompted to respond to CDK4/6 inhibitors.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Bustos MA, Ono S, Marzese DM, et al. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma. J Invest Dermatol. 2017. PMID: 28526299. doi:10.1016/j.jid.2017.03.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。